STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Meldonium

Also known as

Mildronate · MET-88 · meldonium dihydrate

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic Oral / IV Performance / endurance

Systemic metabolic modulator reported orally; intravenous administration appears in medical and pharmacokinetic contexts.

What people say Meldonium is a non-peptide systemic metabolic drug used medically in some countries and prohibited in sport. The reviewed human evidence separates oral repeated exposure from intravenous pharmacokinetic studies. Doses people talk about
Observed single-dose adverse account250 mg oral once

Warmth appeared within an hour, sleep was fragmented and a PEM-like crash was described around 24 hours; severe Long COVID and later lorazepam confounded attribution.

Observed broad self-experiment range500 mg–5 g/day oral

Heavily confounded by steroids, diet and other substances; the author reported almost no stimulation and only slightly faster recovery at 5 g/day.

Recalled prescribed exposure500 mg oral twice daily

One user with ischemia recalled morning and afternoon capsules for about a year and easier physical activity.

Repeated-oral PK cohorts1 or 2 g/day oral

Thirty-two healthy volunteers received one of these daily totals for three weeks in an anti-doping pharmacokinetic study.

These are separate accounts and study cohorts, not an escalation. Medical indication, illness, stacks and product verification differed, and none establishes an advisable self-use amount.

Half-life & effect duration

Half-life in the body
  • Repeated oral useSeveral clearance phases; no single estimate
  • IV study · urine-model phasesAbout 1.4 hours, 9.4 hours and 655 hours — distinct phases
Felt duration people report
  • One accountWarmth within 1 hour; feeling worse around 24 hours
  • Other accountsModest change after several days, or little effect in a large stack
Timing context & sources
How it may feel Reports conflicted: one 250 mg user described warmth, disrupted sleep and next-day worsening; another heavily stacked user found 500 mg–5 g/day barely above placebo; a prescribed user recalled easier physical activity.
Cycles people discuss Observed use ranged from one dose followed by stopping to repeated experiments and about a year of prescribed use. Those records do not establish a universal cycle, and anti-doping detection can persist long after use. Timing Package-style notes describe oral use once or twice daily in four-to-six-week courses. One long-term account reported 500 mg in the morning plus 500 mg in the afternoon—not 500 mg total. These accounts do not establish an optimal clock. Stacks Training-block timing remains preserved community lore, but the inspected accounts do not establish or validate a meldonium stack. Watch for Regulatory risk: Athletes face anti-doping sanctions.
Related
CardarineAICAR

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Repeated oral meldonium showed multiphasic disposition, with several days to steady state and elimination over months.

Thirty-two healthy volunteers received 1 or 2 g/day orally for three weeks in an open-label anti-doping PK study.

The reviewed article does not provide one universal half-life for this repeated oral design; long analytical elimination is not felt duration or efficacy.

Half-life in the body

Three 250 mg IV injections produced distinct 1.4-, 9.4- and 655-hour model phases in urine.

Six healthy volunteers received injections on days 1, 3 and 5; urine was followed for eight months and fit to a three-compartment model.

These are phase-specific urinary-excretion estimates after repeated IV dosing, not one oral half-life and not subjective duration.

Felt duration people report

The inspected reports do not establish a reliable felt-onset or duration window.

One 250 mg report described warmth within an hour and worsening around 24 hours; another described a modest change after several days at 500 mg–1 g, while a heavily stacked account found little effect up to 5 g/day.

Anonymous, unverified and strongly confounded reports across different health states cannot establish causality or prevalence.

What people say 5

  • Performance lore: Athletes discussed endurance benefits — evidence and ethics are contested; banned in competition. forum
  • Community performance reports were mixed: One heavily stacked user described almost no stimulation from 500 mg to 5 g/day and only slightly faster recovery at 5 g/day; a prescribed user with ischemia reported easier activity. forum
  • Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
  • Cardiac/ischemia research: Used clinically in some regions for angina/ischemia-related indications historically. trial
  • Not a hormonal or PCT compound: The reviewed evidence treats meldonium as a metabolic drug with unusual disposition; it does not support inherited androgen-suppression or post-cycle-therapy framing. trial

Doses people talk about 5

  • Athletic misuse talk: forums sometimes copy medical mg charts without cardiac indication — still banned in sport. forum
  • Course culture: multi-week courses (often ~4–6 weeks) rather than indefinite daily use in many package-style writeups. trial
  • Anti-doping: prohibited substance; any use is a testing risk. trial
  • Common medical oral charts (jurisdiction product labels / secondary sources): often ~500–1000 mg/day oral in divided doses for labeled courses (e.g. 500 mg 1–2×/day). trial
  • Framing: Mildronate / meldonium — approved in some countries for cardiac indications; also doping lore. Not FDA-approved US drug. trial

How it may feel 5

  • Single-dose adverse report: A bedbound Long COVID user described warmth within an hour after 250 mg, fragmented sleep, no energy gain and a PEM-like crash around 24 hours, then stopped. forum
  • Repeated community exposure: A heavily stacked user tried 500 mg to 5 g/day and called the effect barely above placebo, with no stimulation and only slightly faster recovery at 5 g/day. forum
  • Prescribed long-term account: One user recalled 500 mg morning plus 500 mg afternoon for ischemia over about a year and said physical activity felt easier; onset was not reported. forum
  • Several-day account: A separate user with about a year of on/off experience described a modest boost only after several days at 500 mg–1 g; the report was uncontrolled. forum
  • Community evidence conflicts: Inspected accounts ranged from no acute energy and next-day worsening after 250 mg, to modest several-day change at 500 mg–1 g, to little effect even at much higher stacked amounts. forum

Cycles people discuss 4

  • Observed durations varied: The inspected records included one 250 mg exposure followed by stopping, repeated 500 mg–5 g/day experiments, and about one year of prescribed use; they do not define a standard course. forum
  • Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
  • No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
  • Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum

Timing 3

  • Oral disposition is multiphasic: In 32 healthy volunteers taking 1 or 2 g/day for three weeks, steady state took several days and elimination continued for months; one universal oral half-life was not reported in the reviewed abstract. trial
  • Intravenous phase estimates: After three 250 mg IV injections in six volunteers, a urinary three-compartment model estimated alpha, beta and gamma half-lives of 1.4, 9.4 and 655 hours. trial
  • Do not collapse routes or phases: Repeated oral exposure and IV urinary-excretion modeling answer different questions; neither establishes how long a user will feel an effect. trial

More on what it is 5

  • Research posture: Educational summary of public discussion and literature themes only. forum
  • What it is: Mildronate (meldonium) metabolic modulator famous from sport doping cases; shifts fatty-acid oxidation lore toward glucose use under ischemia narratives. trial
  • WADA status: Prohibited in sport — major reason for public awareness. trial
  • Not a peptide: Small molecule. trial
  • Research only: Not approved advice for self-experimentation; legality and access vary by place. forum

Stacks 2

  • With training blocks: Timed around camps in old sport lore. forum
  • Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 6

  • Tachycardia / BP changes: Reported in some users. forum
  • Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
  • Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
  • Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
  • Regulatory risk: Athletes face anti-doping sanctions. trial
  • Long elimination / anti-doping detection: Repeated oral and IV studies found multiphasic elimination over months; this is not proof of months-long felt effects. trial

Updated: 2026-08-12

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →